

# “Immuuntherapie” in de hematologie

Gerjo Velders, internist-hematoloog



# De huidige situatie





# Immuuntherapie in de hematologie

- Rituximab
- Daratumumab
- Dasatinib, imatinib, nilotinib
- Ruxolitinib

# Welke immuuntherapie is het?

“-nib”

a protein tyrosine kinase inhibitor, **imatinib**, **ruxolitinib**

“-mab”

a monoclonal antibody (MAB)

“-omab

a mouse MAB (not used in humans therapeutically)

“-ximab

a chimeric (mouse/human) MAB (human constant region + mouse variable immunoglobulin regions) **rituximab**


“-zumab

a humanized MAB (has mouse CDR regions)


“-umab”

a fully human antibody, **daratumumab**


# Rituximab, Mabthera<sup>R</sup>, anti-CD20 Daratumumab, Darzalex<sup>R</sup>, anti-CD38



# CML chronische myeloïde leukemie




# Imatinib (Givec<sup>R</sup>), dasatinib (Sprycel<sup>R</sup>), nilotinib (Tasigna<sup>R</sup>)



Glivec remt CYP3A4 (simvastatine, atorvastatine) en CYP2D6 (levothyroxine en hoge dosis paracetamol)

Sprycel: resoptie wordt verminderd door protonpomprenners en H2 blokkers

# Ruxolitinib Jakavi<sup>R</sup>





Metabolisering in de lever via CYP3A4

Ruxolitinib remt Pgp en BCRP in de darm. Bij gelijktijdig gebruik van dabigatran, rosuvastatine en Digoxine o.a. extra controleren op bijwerkingen van deze middelen.



# Ruxolitinib bij PV en myelofibrose



NB: na het staken van de ruxolitinib treden de klachten meestal < 1 week weer op

